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Aim. Optimal revascularization strategy in multivessel (MV) coronary artery disease (CAD) eligible for percutaneous man-
agement (PCI) and surgery remains unresolved. We evaluated, in a randomized clinical trial, residual myocardial ischemia (RI)
and clinical outcomes of MV-CAD revascularization using coronary artery bypass grafting (CABG), hybrid coronary revas-
cularization (HCR), or MV-PCI. Methods. Consecutive MV-CAD patients (n 155) were randomized (1 :1 :1) to conventional
CABG (LIMA-LAD plus venous grafts) or HCR (MIDCAB LIMA-LAD followed by PCI for remaining vessels) or MV-PCI
(everolimus-eluting CoCr stents) under Heart Team agreement on equal technical and clinical feasibility of each strategy. SPECT
at 12 months (primary endpoint of RI that the trial was powered for; a measure of revascularization midterm ecacy and an
independent predictor of long-term prognosis) preceded routine angiographic control. Results. Data are given, respectively, for
the CABG, HCR, and MV-PCI arms. Incomplete revascularization rate was 8.0% vs. 7.7% vs. 5.7% (p  0.71). Hospital stay was
13.8 vs. 13.5 vs. 4.5 days (p< 0.001), and sick-leave duration was 23 vs. 16 vs. 8 weeks (p< 0.001). At 12months, RI was 5 (2, 9)% vs.
5 (3, 7)% vs. 6 (3, 10)% (median; Q1, Q3) with noninferiority p values of 0.0006 (HCR vs. CABG) and 0.016 (MV-PCI vs. CABG).
Rates of angiographic graft stenosis/occlusion or in-segment restenosis were 20.4% vs. 8.2% vs. 5.9% (p  0.05). Clinical target
vessel/graft failure occurred in 12.0% vs. 11.5% vs. 11.3% (p  0.62). Major adverse cardiac and cerebral event (MACCE) rate was
similar (12% vs. 13.4% vs. 13.2%; p  0.83). Conclusion. In this ¢rst randomized controlled study comparing CABG, HCR, and
MV-PCI, residual myocardial ischemia and MACCE were similar at 12 months. ere was no midterm indication of any added
value of HCR. Hospital stay and sick-leave duration were shortest with MV-PCI. While longer-term follow-up is warranted, these
¢ndings may impact patient and physician choices and healthcare resources utilization.is trial is registered with NCT01699048.
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1. Introduction
/e optimal revascularization strategy in multivessel coro-
nary artery disease (MV-CAD) remains unresolved. /e
longevity of the left internal mammary artery (LIMA) to
LAD graft contributes substantially to the survival benefit of
coronary artery bypass grafting (CABG), while the major
benefit of multivessel percutaneous intervention (PCI) is
lesser invasiveness [1]. With contemporary (2nd generation)
drug-eluting stents (DES), combined restenosis and
thrombosis rate is lower than saphenous vein graft failure
[2, 3]. Excellent outcomes of the LIMA-LAD graft and
favourable outcomes of contemporary DES are the basis for
active consideration of hybrid coronary revascularization
(HCR; LIMA-LAD plus DES-PCI for remaining vessel/s) as
the “third” contemporary revascularization approach to
treat patients with MV-CAD [1, 2, 4–9]. HCR is defined as a
planned intervention combining cardiac surgery with a
catheter-based intervention performed within a predefined
time [2, 4]. HCR employing a combination of a minimally
invasive LIMA-LAD graft procedure with PCI using DES to
non-LAD vessels is receiving increasing attention [10–12]
but it has not yet been evaluated in a clinical trial involving
the two leading MV-CAD revascularization modalities,
CABG and PCI [1].
Single-photon emission computed tomography
(SPECT) myocardial perfusion imaging, with percent is-
chemic myocardium (residual ischemia, RI, calculated by
subtracting the rest from stress total perfusion defect) is not
only an objective method to compare the outcome of cor-
onary revascularization but also there is a direct propor-
tional relationship between RI extent and prognosis [13].
/is makes RI an attractive quantitative endpoint with an
evidenced relationship to long-term cardiovascular events.
HREVS (Hybrid coronary REvascularization Versus
Stenting or Surgery) was designed as the first randomized
controlled study to assess safety and efficacy of the three
contemporary MV-CAD revascularization modalities
employing RI as the quantifiable primary endpoint.
2. Materials and Methods
2.1. Study Design. /e HREVS trial was a prospective,
randomized, open label, multiarm parallel-group, safety and
efficacy study. /e study protocol was approved by the local
ethics committee and it complies with the Declaration of
Helsinki. Written informed consent was obtained from all
study participants. All consecutive patients with angiogra-
phy-confirmed MV-CAD involving LAD and a significant
(≥70% diameter stenosis, DS, on quantitative coronary
angiography, QCA) lesion in at least one major non-LAD
epicardial vessel of ≥2.5mm in diameter, amenable to PCI
and CABG and HCR, were screened by a local Heart Team
(HT). Lesions of 50–70% DS were subjected to functional
evaluation and were considered the study target lesions (i.e,
were labelled for revascularization) if lesion-related myo-
cardial ischemia was present on functional testing (fractional
flow reserve, FFR, or SPECT stress imaging). A list of in-
clusion/exclusion criteria is provided in Appendix A. HT
evaluated all the inclusion/exclusion criteria with a partic-
ular attention given to equal angiographic and clinical
feasibility to perform CABG or HCR or PCI. All consecutive
HT-cleared patients were offered participation in the study.
/ose enrolled in the study (155 out of 204 HT-identified
eligible patients over 31 months; NB. 24%, subjects refused
random allocation of the treatment strategy) were ran-
domized (external randomization on a 1 :1 :1 ratio) to
standard surgical revascularization (CABG with LIMA to
LAD and venous grafts to other vessels as a standard of
reference) or HCR (MIDCAB LIMA-LAD plus PCI for non-
LAD vessel/s) or MV-PCI until all study arms reached 50
subjects. In HCR, MIDCAB LIMA-LAD was always a first-
stage procedure; PCI for the remaining vessels was per-
formed within 3 days from surgery. All PCIs employed
everolimus-eluting CoCr stents (Xience, Abbott Vascular,
Abbott Park, Illinois, USA) as a standard of reference DES
[3]. Treatment was within 7 days from randomization.
Prior to this trial, the study team had built experience in
performing the trial procedures (yearly volume of over 700
CABG with over 100 LIMA-LAD MIDCAB, and over 800
PCIs). /e study was sponsored by the Russian Academy of
Sciences (RAS 056-2013-0012). /e sponsor had no influ-
ence on the study protocol, management, or data analysis.
Primary follow-up point was at 12± 1 months. Analysis
was intention to treat (ITT).
2.2. Primary Endpoint. Primary endpoint was residual is-
chemia at 12± 1months by SPECT, with protocol-mandated
SPECT preceding (by 3–7 days) the protocol-mandated
angiographic control. SPECT protocol and data analysis
were according to those in the COURAGE Nuclear substudy
[13]. In brief, patients underwent a 1- or 2-day protocol with
rest 99mTc sestamibi combined with stress 99mTc sestamibi.
/e percent ischemic myocardium was calculated by sub-
tracting the rest from the stress total perfusion defect.
SPECT analysis was performed in a blinded fashion in an
external nuclear medicine laboratory (Dept. of Nuclear
Medicine, John Paul II Hospital, Krakow, Poland) using
Quantitative Perfusion SPECT software (Cedars-Sinai
Medical Center, Los Angeles, CA, USA).
2.3. Secondary Endpoints. Secondary endpoints included (i)
incomplete revascularization (on a lesion- and patient-ba-
sis), (ii) MACCE (a composite of all-cause death, myocardial
infarction (MI), stroke, and clinically driven target vessel
revascularization) at 30 days and 12 months, (iii) length of
hospitalization, use of postdischarge inpatient institutional
rehabilitation program, and sick-leave duration, and (iv)
target vessel (TV) or graft failure (TFV; a composite of
cardiac death, TV-MI, and clinically driven target vessel
revascularization, TVR) at 12 months after randomization.
For endpoint definitions, see Appendix B.
Angiographic analysis was verified, inclusive of blinded
analysis of baseline angiograms and SYNTAX score calcu-
lation, by an external laboratory using complete angio-
graphic data. Clinical events were adjudicated by an external
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clinical events committee that had access to patient source
data.
2.4. Revascularization, Pharmacological Treatment, and An-
giographic Follow-Up. For the CABG procedure, venous
revascularization (except LIMA to LAD) was performed
according to routine practice in the study centre. In the HCR
group, MIDCAB was always a first-stage procedure and it
was followed, within 3 days, by PCI.
Aspirin was prescribed before revascularization for all
study patients and it was continued indefinitely. For PCI
(including HCR PCI), UFH was used (i.v. bolus of 100 IU
per kilogram body weight followed by adjustment according
to target-activated clotting time of 250 to 300 seconds).
Antiplatelet regimen included clopidogrel routinely (loading
dose of 300mg at the time of PCI unless used in advance;
then 75mg daily, recommended duration of treatment
12months) and aspirin (75mg once daily) indefinitely.
Complete revascularization was defined as successful re-
vascularization, by means of either surgery (bypassing) or PCI
(stenting), of all HT-determined target lesions. Incomplete
revascularization was evaluated on a lesion- and patient-basis.
Any potential angiography (±PCI) performed for clinical
reason(s) prior to the study primary follow-up point had no
influence on adhering to protocol-mandated angiographic
control at 12± 1 months.
Postprocedure lifestyle modification and medication
regimen were according to guideline recommendations.
2.5. Statistical Analysis. Central database management and
statistical analysis were external. For the primary endpoint,
RI differences between the study arms (with CABG taken as
reference) were tested against a prespecified noninferiority
margin of 4.2 percentage points based on literature data of
the clinically relevant threshold of RI difference (see Ap-
pendix D). p values <0.025 were considered significant to
adjust for two comparisons of the primary endpoint. In
addition, comparison of each vs. each revascularization
method was performed with the RI differences between the
study arms (expressed as positive values) tested against a
prespecified noninferiority margin of 4.2 percentage points
and the p value spending function to calculate overall type I
error rate. /us, the additional analysis was deliberately
performed in absence of defining a reference method of
MVD revascularization. To control type I error rate, we
calculated the overall type I error rate in three pairwise
comparisons of the treatment arms from the formula
(1 − ptotal) � (1 − p1) × (1 − p2) × (1 − p3), and ptotal was
considered statistically significant when <0.05.
For comparisons of secondary endpoints and clinical
characteristics, nominal p values <0.05 were considered
significant. Power calculations are described in Appendix C.
3. Results
One hundred and fifty-five consecutive patients with MV-
CAD, who met the inclusion/exclusion criteria, were ran-
domized to CABG (n� 50), HCR (n� 52), or MV-PCI
(n� 53) following HT agreement on equal technical and
clinical feasibility of each of the 3 coronary revascularization
modes. Baseline clinical and procedural characteristics of the
study patients are shown in Table 1. Of note, the mean age
was 62± 7 years, and the majority of the patients were males
(71.6%). More than one half of the patients had a prior MI
(55.5%). Left ventricular ejection fraction (LVEF) was
54.5± 8.0%. One half of the study patients had 2-vessel
disease (50.3%), whereas ≥3 vessel CAD was present in the
other half (49.7%). Mean angiographic SYNTAX Score was
19.4± 2.9, whereas EuroScore II was 1.71± 0.76. Baseline
characteristics were similar between the study arms
(Table 1). Numbers of diseased vessels and index lesions as
well as CR stents and grafts are given in Table 1.
/e HCR patients, except 5 (9.8%) who required con-
version to CABG (Table 2), had per-protocol PCI within 3
days (in most cases at 24–48 h) after performing MIDCAB
LIMA-LAD anastomosis that was always the first stage of
HCR. /e reasons for HCR conversion to conventional on-
pump CABG with median sternotomy were either technical
surgical (n� 2) or there was hemodynamic instability fol-
lowing LIMA-LAD grafting that required other lesions’
revascularization on an ad hoc basis (n� 3). All other pa-
tients in the HCR group (47/52) continued to the PCI stage
of HCR and underwent, at that point, angiographic LIMA
control. /is showed LIMA thrombotic occlusion in 1 case
(2.1%) resolved by PCI of the native artery, LAD, using the
study DES. /us, the HCR LIMA immediate patency rate
was 46/47 (97.9%). Patent LIMAs and native LADs showed
TIMI-3 flow in absence of any anastomosis stenosis >50%
DS that might warrant considering a need for intervention.
Target coronary revascularization was incomplete, on a
per-lesion basis, in 3.7% (5/136) in the CABG group versus
2.7% (4/149) and 2.1% (3/146) lesions in the HCR and PCI
groups, respectively (p � 0.71). On a per-patient basis, in-
complete revascularization rate was 8.0% (4/50) vs. 7.7% (4/
52) vs. 5.7% (3/53) patients (p � 0.86) (Table 1).
Bleeding wasmore prevalent, and it was greater (for BARC
evaluation see Table 2), in the study arms involving surgery.
/ere were 4 transfusions in CABG (8.0%), 2 in HCR (3.9%),
and none in the MV-PCI arm (p � 0.066). /ere was one
death ≤30 days that occurred in the HCR group (the patient
experienced periprocedural MI and stroke that led to death).
/e length of hospitalization, use of inpatient rehabili-
tation, and sick-leave duration were higher with surgery
(CABG or HCR), with hospitalization length and institu-
tional rehabilitation similar in the CABG and HCR arms
(Table 2). /irty-day MACCE rate was 8% vs. 5.8% vs. 3.8%
(respectively, CABG, HCR, and PCI, p � 0.37), and it was
driven mainly by periprocedural MI (Table 2).
At 12± 1 months, all alive patients (n� 149) underwent
protocol-mandated SPECT that was followed by protocol-
mandated control angiography. None of the 5 patients with
repeat revascularization prior to the primary follow-up at
12± 1 months (Table 1) was alive at the point of protocol-
mandated SPECT (5 out of 6 deaths before 12± 1 months
occurred in patients with repeat revascularization).
Median RI at 12 months was mild in all study arms; 5 (2,
9)% vs. 5 (3, 7)% vs. 6 (3, 10)% (median; Q1, Q3) with the
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noninferiority p values of 0.0006 (HCR vs. CABG) and 0.016
(MV-PCI vs. CABG). Between-group differences were sig-
nificantly smaller than the prespecified noninferiority
margin of 4.2% and the trial met its primary endpoint of
noninferiority (Figure 1). /e ITT-based conclusion was the
same when patients with conversion from HCR were ex-
cluded (per protocol analysis) and when the patients with
conversion from HCR were reclassified to the CABG group
(per treatment analysis). /ere were no differences in the
primary endpoint in patients with 2-vessel disease vs. >2-
vessel disease. /ere were also no differences according to
SYNTAX score. Proportion of patients with RI>5% was
similar in all three treatment modalities (CABG 20/49,
40.8%; HCR 21/49; 42.9%; MV-PCI 26/51; 51.0%, p � 0.56).
As shown in Figure 2, the three treatment modalities were
associated with a similar freedom from MACCE at 12
months.
Angiographic control at 12 months demonstrated 9
SVGs and 1 LIMA stenosis/occlusion in the CABG group
(10/49, 20.4%), 3 LIMA stenoses/occlusions and 1 in-
segment restenosis in the HCR group (4/49, 8.2%), and 3
in-segment restenoses in the PCI group (3/51, 5.9%);
p � 0.05. Twelve-month TV or graft failure (composite of
cardiac death, TV-MI, and clinically driven TVR) was
Table 1: Baseline and procedural characteristics according to randomization arm∗.
Characteristic CABG (n� 50) HCR (n� 52) PCI (n� 53) p
Age (years) 61.3± 6.8 62.0± 7.4 61.7± 7.7 0.80
Male sex 70.0% (35) 75.0% (39) 69.8% (37) 0.90
Current smoking 50.0% (25) 46.1% (24) 47.2% (25) 0.92
Arterial hypertension 66.0% (33) 65.4% (34) 67.9% (36) 0.96
Diabetes mellitus 22.0% (11) 17.3% (9) 20.7% (11) 0.83
Chronic kidney disease 0% (0) 1.9% (1) 5.7% (3) 0.32
COPD/BA† 4.0% (2) 7.7% (4) 11.3% (6) 0.43
Previous MI‡ 56.0% (28) 51.9% (27) 58.5% (31) 0.79
Prior stroke 6% (3) 7.7% (4) 5.7% (3) 0.92
Peripheral vascular disease 24.0% (12) 30.8% (16) 30.2% (16) 0.70
LVEF (%)§ 54.0± 7.4 56.2± 6.3 53.3± 9.9 0.159
LVEF≤45% 12% (6) 5.8% (3) 20.8% (11) 0.070
EuroSCORE IIǁ 1.70± 0.76 1.71± 0.72 1.70± 0.79 1.0
Affected vessels:
2 42.0% (21) 51.9% (27) 56.6% (30)
≥3 58.0% (29) 48.1% (25) 43.4% (23) 0.32
Affected vessels (mean) 2.7± 0.6 2.5± 0.6 2.5± 0.6 —
No. of index lesions
2 42.0% (21) 36.5% (19) 50.9% (27)
3 44.0% (22) 42.3% (22) 30.2% (16)
>3 14.0% (7) 21.2% (11) 18.9% (10) 0.35
No. of index lesions (mean) 2.7± 0.7 2.9± 0.8 2.7± 0.9 —
{SYNTAX score 19.3± 3.0 19.4± 3.0 19.5± 2.7 0.91
No. of grafts
1 0% (0) 90.4% (47) —
2 46.0% (23) 5.8% (3) —
≥3 54.0% (27) 3.8% (2) — NA
Arterial grafts 37.8% (50) 77.6% (52) — NA
Venous grafts 62.2% (82) 22.4% (15) — NA
No. of grafts (mean) — —
No. of stents
0 2.6± 0.7 1.1± 0.4
1 — 9.6% (5) 0
2 — 48.1% (25) 0
3 or more — 32.7% (17) 51.9% (27) NA
No. of stents (mean) — 9.6% (5) 49.1% (26) —
— 1.5± 0.9 2.7± 0.9
Incomplete TLRΦ (per patient) 8.0% (4) 7.7% (4) 5.7% (3) 0.86
Incomplete TLRΦ (per total number target lesions in
study group) 3.7% (5/136) 2.7% (4/149) 2.1% (3/146) 0.71
Values are means± SD or percentages (counts). Data are shown as per randomization (intention-to-treat population). CABG: coronary-artery bypass
grafting; HCR: hybrid coronary revascularization; PCI: percutaneous coronary intervention. †COPD/BA: chronic obstructive pulmonary disease/bronchial
asthma. ‡MI: myocardial infarction. §LVEF: left ventricular ejection fraction. ǁEuroSCORE II: /e European System for Cardiac Operative Risk Evaluation
(EuroSCORE); a clinical model for calculating the risk of death after cardiac surgery. {SYNTAX score: Synergy between PCI with Taxus and Cardiac Surgery
(SYNTAX) score; an angiographic model for evaluating coronary artery disease extensiveness. ΦTLR, target lesion revascularization, given per total number
of lesions to be revascularized according to Heart Team recommendation.
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12.0% (CABG) versus 11.5% (HCR) versus 11.3% (PCI)
(p � 0.99). Angiography-driven revascularization was
performed in 1 of 50 (2.0%) CABG patients versus 12/105
(11.4%) subjects with any PCI at baseline (combined HCR
plus MV-PCI arm) (p � 0.062). As shown in Table 2, total
TVR rate (sum of clinically driven and control
angiography-driven) at 12 months numerically favoured
CABG, with 4.0% (CABG) versus 13.5% (HCR) versus
17.0% (PCI) (p � 0.095), and 4.0% in the CABG arm (2/
50) but 15.2% (16/105) in the combined HCR plus MV-
PCI cohort (p � 0.058; for individual group data, see
Table 2).
Table 2: HREVS study endpoints according to randomization group.
Endpoint CABG HCR PCI p value
Primary endpoint at 12 months∗
N� 49 N� 49 N� 51
RI (SPECT) 6.7 (4.6, 8.8) 6.4 (4.3, 8.5) 7.9 (5.9, 9.8) 0.45∗∗
Secondary endpoints at 12 months
N� 50 N� 52 N� 53
MACCE (death/stroke/MI/clinically driven repeat
revascularization) 12.0% (6) 13.4% (7) 13.2% (7) 0.83
Death 2.0% (1) 5.8% (3) 3.8% (2) 0.78
Stroke 0% (0) 3.8% (2) 0% (0) 0.21
MI 8% (4) 5.8% (3) 7.5% (4) 0.66
Clinically driven TVR 2.0% (1) 1.9% (1) 5.7% (3) 0.54
Angiography-driven TVR 2.0% (1) 11.5% (6) 11.3% (6) 0.139
Total TVR 4.0% (2) 13.5% (7) 17.0% (9) 0.095
Secondary endpoints at 30 days
MACCE (death/stroke/MI/clinically driven repeat
revascularization) 8% (4) 5.8% (3) 3.8% (2) 0.37
Death 0% (0) 1.9% (1) 0% (0) 0.66
Stroke 0% (0) 1.9% (1) 0% (0) 0.66
MI 8% (4) 5.8% (3) 3.8% (2) 0.37
Repeat revascularization 0% (0) 1.9% (1) 0% (0) 0.66
Conversion to CABG NA 9.6% (5) 0 0.027
Bleeding
BARC 0–1 80.0% (40) 80.8% (42) 98.1% (52)
BARC 2 0% (0) 9.6% (5) 1.9% (1)
BARC 3–4 20.0% (10) 9.6% (5) 0% (0) 0.001
Hospital stay (days) 13.8 (12.5, 15.1) 13.5 (12.2, 14.8) 4.5 (3.2, 5.8) <0.001
Institutional rehabilitation 100% (49) 97.9% (48) 56.8% (29) <0.001
Sick leave (weeks) 23 (21, 25) 16 (15, 18) 8 (6, 10) <0.001
Data are presented as means (95% confidence interval) or percentages (counts). ∗Evaluable in patients alive at 12± 1 months. ∗∗p � 0.046 on combined
noninferiority analysis that the study was powered for (cf. Figure 1).
MV-PCI vs. CABG
p = 0.016
HCR vs. CABG
p = 0.0006
–3 –2 –1 0 1 2 3 4 5 6–4
Difference in residual ischemia at 12 months
(a)
CABG vs. HCR
(p = 0.029)
MV-PCI vs. HCR
(p = 0.003)
MV-PCI vs. CABG
(p = 0.015)
–3 –2 –1 0 1 2 3 4 5 6–4
Difference in residual ischemia at 12 months
(b)
Figure 1: Noninferiority analysis for the SPECT-based residual ischemia at 12months in the three treatment arms with CABG as a reference
method (a) and assuming no single reference method (b). Point estimates and 90% confidence intervals for the differences in RI between
treatment modalities are shown with solid vertical gridline indicating the null difference and interrupted vertical gridline indicating the
noninferiority margin of 4.2 percentage points. (a) Respective p values are for noninferiority of MV-PCI vs CABG and HCR vs. CABG. To
adjust for two comparisons with CABG as the reference p values were considered statistically significant when <0.025. (b) p values are for
pairwise noninferiority tests with 95% one-sided confidence intervals. Overall p for noninferiority is 0.046.
Journal of Interventional Cardiology 5
4. Discussion
/e primary endpoint of this first randomized controlled
study, comparing conventional CABG, MV-PCI using 2nd
generation standard-of-reference DES, and HCR in patients
with MV-CAD amenable to treatment with any of the three
guideline-accepted modalities, was SPECT-determined RI at
12 months. Based on the noninferiority margin of the trial,
the three strategies were similar after 12 months in terms of
RI (Figure 1) that is an established measure of CR efficacy
and a predictor of long-term prognosis. Other important
findings, with potential relation to healthcare resources’
utilization, are shorter hospital stay, less need to use insti-
tutional in-patient rehabilitation, and shorter sick-leave
duration with the percutaneous route of coronary revas-
cularization in MV-CAD. Although underpowered for
clinical events, HREVS suggests similar 12-month MACCE
rates with all three treatment strategies (Figure 2), a finding
that requires confirmation in a larger multicentre study.
/e primary focus of HREVS is RI at 12 months by
SPECT. Myocardial perfusion SPECT imaging is not only an
objective method to compare the outcome of coronary re-
vascularization but also there is a direct proportional rela-
tionship between the extent of RI and prognosis [14, 15].
Taking into account that the groups were randomized,
comparable in their basic characteristics, and the fact that
the groups received high level of complete revascularization
(92% vs. 92.3% vs. 94.3%), it can be concluded that within
the assumed noninferiority margin, the three strategies
occurred similar with respect to RI at 12 months. /is main
result is broadly consistent with the analysis of the secondary
endpoints (Table 2, Figure 2).
/e two typically applied techniques for MV-CAD
interventional management, CABG and MV-PCI, have
clinically relevant disadvantages that include the
invasiveness of CABG and the increased risk of repeat re-
vascularization with PCI [2, 16]. /e optimal revasculari-
zation approach would thus need to combine a decreased
invasiveness plus low risk of perioperative complications
and an increased durability and survival. A combination of a
minimally invasive LIMA-LAD graft procedure with PCI
using DES to non-LAD vessels eliminates aortic manipu-
lation and extracorporeal circulation, resulting in a potential
to decrease the risk of perioperative complications
[1, 4, 11, 12, 17]. /us, the “third” revascularization strat-
egy—HCR—might have potential advantages beyond PCI
and CABG alone [1, 4–12, 18, 19]. Although HCR was first
introduced over 20 years ago [4], today the potential of this
strategy in MV-CAD patients appears neither sufficiently
determined [1, 2, 10] nor fully utilized [9, 19]. Some fun-
damental HCR concerns include the complexity of patient
logistics; the presence of surgical and endovascular stage
(with “naturally” incomplete revascularization at the HCR
first-stage); the timing of antiplatelet therapy, optimal
timing of the HCR stages; and technical aspects of the
surgical intervention (access site, and the role of thoraco-
scopic or robotic approaches) [5–11].
/us far, HCR outcomes have been compared mostly
with standard CABG [1, 6, 8], and included only one ran-
domized study that, however, did not have a percutaneous
treatment arm [6]. Another observational study compared
conventional CABG to MV-PCI [18]. Retrospective series
and meta-analyses have reported low mortality rates (0% to
2%) and event-free survival rates of 83% to 92% for HCR at 6
to 12 months of follow-up and similar outcomes of HCR in
comparison with standard revascularization options [5, 8].
In the single randomized trial of HCR vs. conventional
CABG, the HCR arm demonstrated, at 12 months, similar to
CABG cumulative occurrence of major adverse cardiac
events [6]. In that study, 6.1% HCR patients required
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Figure 2: MACCE-free survival (a) and cumulative risk of MACCE (b) during 12-month follow-up according to the treatment arm. Panel A
showsMACCE-free survival, whereas the cumulative risk of MACCE is depicted in Panel B. Numbers of patients at risk are shown above the
horizontal axis in panel A. Pairwise comparisons of treatment arms with Cox proportional hazards model are shown at the bottom of panel
B. MACCE—Major Adverse Cardiac or Cerebral Event.
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conversion to standard CABG [6], a result broadly consis-
tent with our present findings (Table 2).
HREVS is the first randomized controlled study com-
paring outcomes of the three guideline-accepted treatment
strategies in MV-CAD patients. In HREVS, the HCR pa-
tients underwent two-stage revascularization with MIDCAB
first, followed by PCI using the second-generation ever-
olimus-eluting stents. /e use of a standard-of-reference
[3, 20, 21] 2nd generation DES in HREVS, the device that
showed some of the best results in the interventional
treatment of CAD patients, suggests that HREVS patients
were offered a maximized benefit from the choice of stent
in the endovascular arm and in the HCR arm.
Prior work indicated that MIDCAB, when compared to
conventional sternotomy CABG, results in less surgical
trauma, decreased risk of bleeding and infectious compli-
cations, and may shorten the length of hospitalization
[4, 11, 12]. /e latter, however, is not supported by our
findings, a result that may be partly driven (note ITT
analysis) by the conversion rate (9.8%) from HCR to CABG
in HREVS (Table 2).
In the HREVS HCR arm, PCI was performed within 3
days after surgery (in majority of patients, within 24–48 h
after surgery). /is allowed consistency of hemostasis in
absence of DAPT at the time of surgery (the patients were
operated on aspirin and loaded with clopidogrel at the time
of PCI) as well as angiographic control of the LIMA-to-LAD
graft during the endovascular stage. Lack of ad hoc total
revascularization in the HCR group with LIMA-to-LAD
MIDCAB, however, was associated with hemodynamic in-
stability and myocardial ischemia in 3 patients who required
conversion to sternotomy to perform ad hoc revasculari-
zation of the remaining lesions by CABG.
Although HREVS will continue to monitor its study par-
ticipants up to 5 years, a larger multicentre study involving
HCR along CABG and MV-PCI would be required to deter-
mine, by clinical outcomes, the optimal interventional treat-
ment strategy in MV-CAD. /is is relevant also because
evidence is accumulating that using multiple arterial grafts in
CABG may be associated with improved clinical outcomes
when compared to either conventional CABG with LIMA to
LAD and SVGs to other vessels [22], CABG using bilateral
mammary arteries plus SVGs [23], or to MV-PCI [24]. Al-
though HREVS indicates no significant differences in 12-
month TVF between the three treatment modalities, the an-
giographic control at 1 year suggested sizable differences in
graft stenosis/occlusion or in-segment restenosis rates (20.4%
vs. 8.2% vs. 5.9% for CABG vs. HCR vs. MV-PCI; p � 0.05)
that may affect long-term outcomes [25]. Whether these dif-
ferential 12-month anatomical revascularization results affect
longer-term clinical outcomes [25] remains to be established.
Importantly, the lower rates of institutional rehabilita-
tion use in the MV-PCI arm are not necessarily beneficial
because the patients who opt not to use the institutional
rehabilitation services might benefit from those.
/e prevalence and extent of bleeding with (any) surgery
(Table 2) should serve as an important consideration point
in support of PCI rather than CABG or HCR in some (if not
most of) moderate SYNTAX patients.
A recently funded US National Institutes of Health
(NIH) Hybrid Coronary Revascularization Trial (HCR,
NCT03089398), a 2354 patient study with 5-year follow-up,
might be able to overcome only some of the HREVS lim-
itations because the NIH HCR Trial compares HCR vs. MV-
PCI in absence of the CABG arm.
4.1. Limitations. /is study has several limitations as listed
below.
(i) HREVS was not powered for clinical events, al-
though the center enrolment rate and volume
exceeded by over 10-fold typical yearly contribu-
tions in the pivotal BEST Trial comparing MV-PCI
with CABG that was itself underpowered due to an
insufficient and slow enrolment that included only
20% of the eligible patients [20].
(ii) Recruitment challenges were related not only to the
fundamental requirement of equal technical and
clinical feasibility of either of the tested strategies
but also to the patient’s (and family’s) natural
gravitation towards less invasive treatment (evi-
denced by nearly 1 in 4 refusal rate to random
treatment allocation due to PCI preference); thus,
overall recruitment rate in HREVS was >75%.
(iii) HREVS did not evaluate quality of life, an area
where clinically relevant differences might exist,
consistent with our findings on the sick-leave du-
ration and time-to-return to work, favouring less
invasive treatment strategies.
(iv) Any generalizability of the findings needs to take
into account the moderate MVD angiographic
complexity in this study (reflecting the requirement
of technical feasibility of CABG, HCR, and MV-
PCI; thus, the need to exclude the left main coronary
artery stenosis not amenable to HCR, severely
calcific lesions, complex bifurcations, or chronic
total occlusion that may favour surgery) and the
particular sequence and timing of HCR procedures
as per the HREVS protocol.
4.2. Strengths. Fundamental strengths of HREVS include the
following:
(i) Use of quantifiable primary endpoint of RI at
12months that is independently predictive, in a
gradient manner, of cardiac death or MI
[13–15, 26], and the trial appropriate power for
noninferiority comparison of the 3 treatment
modalities [13, 27].
(ii) /ere were no identifiable clinical or angiographic
differences between the patients who agreed to
random treatment allocation in HREVS and entered
the study versus those whowereHeart Team–labelled
as eligible for enrolment but did not accept random
treatment allocation, in favour of generalizability of
the findings to similar patients outside the trial.
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(iii) Mandatory angiographic control at 12months is a
particular strength of the present study as it
verified the midterm anatomic quality of
revascularization.
(iv) HREVS results add importantly to the present
knowledge in the context of (a) increasing pene-
tration of percutaneous revascularization [28], (b)
suggestions that optimized PCI might lead to
CABG-like outcomes in MV-CAD [29], and (c)
increasing Heart Team recommendations of first-
line percutaneous approach [2, 28].
(v) Rather than generating hypotheses on the basis of
historical comparative data [29], HREVSwas a real-life
randomized trial with multiarm parallel-group design.
5. Conclusion
In patients with MV-CAD amenable to CABG, HCR, and
MV-PCI, the quantitative endpoint of residual myocardial
ischemia at 12 months, which is predictive in a gradient
manner of cardiac death and adverse cardiac events
[13–15, 26], was similar with all three guideline-
accepted revascularization strategies. MV-CAD PCI, using
contemporary best-in-class drug-eluting stents, was
associated with a shorter hospital stay, less inpatient reha-
bilitation, and shorter sick-leave duration than CABGorHCR.
While extended follow-up will determine longer-term
outcomes from the present study, a larger-scale multicentre
trial powered for clinical endpoints would be warranted.
Nevertheless, any effective execution of such a large-scale
study seems unlikely [20].
Appendix
A. HREVS Trial Inclusion/Exclusion Criteria
Table 3 shows the inclusion and exclusion criteria of the
HREVS trial.
B. Endpoint and Other Definitions
MI and stroke were defined according to international
guidelines (1, 2); other definitions were according to the
Academic Research Consortium (3). In brief, clinically driven
TVR was defined as percutaneous revascularization or bypass
of the target lesion or any segment of the epicardial coronary
artery containing the target lesion or more proximal vessels
that may have been traversed by the angioplasty guidewire
during the index procedure, driven by ischemic symptoms
presence or presence of other clinical abnormalities leading to
an angiogram prior to the protocol-mandated point at 12± 1
months from randomization. Angiography-driven TVR was
TVR resulting from performing protocol-required control
angiography at 12±1 months. Target vessel (TV) or graft
failure was defined as a composite of cardiac death, target
vessel-MI, and clinically driven TVR of the artery containing
the target lesion (i.e., one of the index lesions in a given
patient) within 12 months after randomization (3).
C. Power Calculations
Power calculations and statistical analysis are consistent with
reference 4 and reference 5. With recruitment of 50 subjects
per group, the study had 80% power to exclude with a
Table 3: Inclusion and exclusion criteria of the HREVS trial.
Inclusion criteria Exclusion criteria
1. Male or female ≥18 years of age
2. II–IV Canadian Cardiovascular Society functional
class of angina
3. Angiographically confirmed multivessel coronary
artery diseases involving LAD, with lesions severity
≥70% diameter stenosis (DS) by quantitative
coronary angiography (QCA), or 50–70% DS with
functional evidence of ischemia by either FFR ≤0.80
or stress SPECT
4. At least 1 month after acute MI (in patients with
history of MI)
5. Heart team-determined indication to coronary
revascularization with equal feasibility to perform
complete revascularization using either of the three
methods (HCR, MVD-PCI, CABG)
6. Written informed consent for participation in the
study, including random treatment allocation and
compliance with study requirements inclusive of
follow-up visits and 12± 1 month SPECTfollowed by
control angiography
1. Acute coronary syndrome (ACS)
2. Any previous coronary revascularization (CABG,
HCR, or PCI)
3. Presence of any condition or abnormality that in
the opinion of the investigator would compromise
the safety of the patient or the quality of the data
4. Pregnancy
5. Stenosis of the left main coronary artery requiring
revascularization
6. Significant calcification or occlusion of a major
coronary vessel
7. Left ventricle aneurysm or valvular heart disease
requiring surgical management
8. Comorbidity associated with an increased
procedural risk for any of the treatment strategies or
other study procedures
9. Peripheral arterial disease with pain-free walking
distance ≤50m
10. Life expectancy ≤5 years
11. Inability to comply with dual antiplatelet therapy
(DAPT)
12. Inability to undergo follow-up procedures
including long-term follow-up
13. Participation in another clinical study
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noninferiority t-test with the 2.5% type I error rate (adjusted
for two comparisons with the reference arm), the margin set
at 4.2 percentage points, which we considered a reasonable
minimum clinically significant difference. An absolute 4.2
percentage points difference is associated with an increased
risk of MI, whereas 4.9 percentage points is cut-off for an
increased risk of death (6, 7), and the generally accepted
clinically significant ischemia interval is set at 5%, with 5%
considered a clinically significant difference (8, 9). Based on
literature data (8), the assumed standard deviation of per-
cent ischemic myocardium was 7.
D. Additional Information on Statistical
Analysis and Study Conduct and Reporting
/e continuous variables are presented as the mean± SD,
unless with skewed distribution, for which medians with
quartiles are presented. /e categorical variables are sum-
marized as percent and count. Study endpoints were reported
as means± SD with 95% confidence intervals or as percent-
ages, where applicable. Analysis was intention to treat. Con-
tinuous variables were compared using unbalanced ANOVA
when distributions were approximately normal. Kruskal–
Wallis test was used to compare medians of significantly
skewed variables. Proportions were compared with the chi2
test or the Fisher exact test, as appropriate. A noninferiority
analysis for the primary endpoint was performed using the
t-distribution-based confidence intervals assuming a non-
inferiority margin of 4.2 RI percentage points. To adjust for
two comparisons with CABG as the reference p values were
considered statistically significant when <0.025. A 2-sided
nominal p value <0.05 was considered statistically significant
in secondary endpoint analysis. Product-limit survivor func-
tion estimate was used in MACCE analysis, and Cox pro-
portional hazards model was applied to estimate hazard ratios
of MACCE between study arms. Statistical analysis was per-
formed with SAS 9.4 software (SAS Institute, Cary, NC, USA).
HREVS study conduct and reporting were consistent
with the updated CONSORT 2010 guidelines [10].
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CABG: Coronary artery bypass grafting
DAPT: Dual antiplatelet therapy
FFR: Fractional flow reserve
HCR: Hybrid coronary revascularization
HT: Heart team
MACCE: Major adverse cardiac and cerebrovascular
events (death/stroke/myocardial infarction
(MI)/clinically-driven TVR)
MIDCAB: Minimally invasive direct coronary artery bypass
MV-
CAD:
Multivessel coronary artery disease
PCI: Percutaneous coronary intervention
RI: Residual myocardial ischemia
SPECT: Single-photon emission computed tomography
TVR: Target vessel revascularization
TVF: Target vessel failure.
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